Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OREX
Orexigen 1Q Contrave Net Sales $11.5M >OREX *
Friday 05/08/2015 07:02 AM ET - Dow Jones News
OREX
PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) will announce financial results for the first quarter 2015 on Friday, May 8 before the market opens. The announcement will be followed by a live webcast and conference call at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time).
OREX
Should be a good report IMO in AM before market opens.
We should see effects of the Contrave launch.
Well done!!
I sold in the 7's.
Great pick!!
BTW: OREX is a bargain right now at $6.46
Earnings Friday before the opening bell.
Should be trading in the high 8's
OREX
Looking forward to financials coming out on Friday May 8 before market opens
Me too.
Ultimately, sales numbers/ prescription numbers will drive the SP up.
I'm in here for the 2 quarters at least.
OREX
Seems way oversold.
Contrave launch is ahead of schedule and now with EU approval.
Earnings next month should drive the SP north IMHO
OREX
Getting hit hard the last few days.
Looks like a great re-entry point here now.
Looks oversold to me. Should climb into what should be positive earnings report next month.
RPRX
Getting hammered here lately.
OREX
Big boys playing hard ball here.
Orexigen: Orexigen, Takeda Plan To Vigorously Enforce Contrave Intellectual Property Rights >OREX *
Wednesday 04/22/2015 07:32 AM ET - Dow Jones News
OREX
Orexigen: Orexigen, Takeda Plan To Vigorously Enforce Contrave Intellectual Property Rights >OREX *
Wednesday 04/22/2015 07:32 AM ET - Dow Jones News
Results are very good and sales are excellent.
Headed to $10 IMHO
I added a bit more.
Numbers will look very good soon enough IMO.
Too many positives ahead.
US sales are doing great with over 700 Takeda reps
And now EU approval.
Earnings should be very positive.
I'm a buyer here on any weakness like today
Yep
I just picked up a nice block at 7.41
Something's up today?
Big bid pre-market at 7.75
Partnership news?
OREX
Somebody wants a lot of shares this morning.
Thanks
Days like today are great days to buy quality.
Ok
Thanks.
I just took a small bite at $8.4056
Hi
What's going on with RPRX?
ATHX
Lol. I hear you.
I bought a block this AM around $1.03.
Just sold out at $1.31.
? Dead cat bounce.
I agree with you.
I'm just saying that it looks like there is a role for the treatment if you can get it early.
Kind of like getting clot busters for heart attack if you can get it within 4 hours.
I guess, in just saying that I had a stroke, I would want to get the treatment as fast as possible.
There should be a place for it perhaps in another study that looks at administration within 12 hours of stroke symptoms.
LN
m;
The MultiStem treatment group had a lower rate of life threatening adverse events and death (p=0.04), and also exhibited lower rates of pulmonary events (p=0.08) and infections. The MultiStem treated group also had a significantly lower level of circulating CD-3+ T-cells at two days following dosing (p<0.01), suggesting a reduction in the inflammatory response post-stroke, consistent with the therapeutic hypothesis.
As noted above, post-hoc analyses show that earlier MultiStem administration appears to provide substantial benefit, as evident in the following
however;
Among all subjects who received MultiStem treatment, 15.4% of patients achieved an Excellent Outcome, defined clinically as attaining mRS 0-1, NIHSS 0-1 and BI >=95, compared to 6.6% of patients that received placebo, (p=0.10);
As described in the table below, patients who received MultiStem treatment earlier in the treatment window (24-36 hours post-stroke) exhibited more favorable recovery on the primary and key secondary endpoints than patients who received placebo or patients who received MultiStem treatment later (e.g. Excellent Outcome, p = 0.03), and this treatment effect was even more pronounced the earlier the MultiStem administration within the 24-36 hour timeframe;
ATHX
I just picked some up at $1.03
Looks like a typical over-reaction to me.
Patients had lower mortality and fewer complications.
That's what I was doing as well considering I made some good coin on this one already.
I bought back in at an acceptable rate for me.
I agree with your 49% downside assessment, so I bought back only 25% of my shares at 2.20
If the results on Sunday are good, we should see a respectable up gap on Monday ore-market.
Good luck to us on this one.
It's a pure Vegas move here but I'm strictly betting part of the house's $ here.
The science looked good to me.
I cashed out around 3.12 but I got back in today at $2.20 with a smaller position.
There is a decent chance that the phase 2 data will be positive and since the presentation is in Scotland on Sunday morning, I don't want to miss the gap up on Monday if the data is favorable.
It's a gamble either way I guess.
Thanks
ATHX
Does anyone know what happened here?
Looks like it could be a good bounce play right now?
OREX
BTW: this one has held up nicely and is primed to move North quickly IMO.
Management has been spot on with this one and now with EU approval?
I continue with my initial PT of $10
Yes
Absolutely correct
Wow
I hadn't seen that
I had gotten out around 3.12
Not sure why the drop?
CUR
Big move today!!
CUR
Awesome buying opportunity IMHO under $2
Good science and great market potential!
Sub-2's won't last.
CUR is an awesome buy down here.
Good science and great market.
I continue to accumulate under $2
Get this back up to .30
TGTX
Just bought the dip at $15.57
ATHX
Out at 3.12 for a nice gain from 2.83 entry.
GLTA
I'm out again.
Another easy flip